NCT03444701View on ClinicalTrials.gov

A Study of E7130 in Participants With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions
Solid Tumors
Interventions
DRUG

E7130

Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1.

DRUG

E7130

Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.

Trial Locations (9)

Unknown

Eisai Trial Site 9, Nagoya

Eisai Trial Site 1, Kashiwa

Eisai Trial Site 6, Kashiwa

Eisai Trial Site 8, Sapporo

Eisai Trial Site 4, Sendai

Eisai Trial Site 5, Chuo-ku

Eisai Trial Site 7, Bunkyo-ku

Eisai Trial Site 3, Chuo-ku

Eisai Trial Site 2, Koto-ku

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT03444701 - A Study of E7130 in Participants With Solid Tumors | Biotech Hunter | Biotech Hunter